RT Journal Article SR Electronic T1 Germline rare deleterious variant load alters cancer risk, age of onset and tumor characteristics JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.02.21259537 DO 10.1101/2021.07.02.21259537 A1 Myvizhi Esai Selvan A1 Kenan Onel A1 Sacha Gnjatic A1 Robert J. Klein A1 Zeynep H. Gümüş YR 2021 UL http://medrxiv.org/content/early/2021/07/07/2021.07.02.21259537.abstract AB Background Inherited genetic variants play an important role in cancer susceptibility. Recent studies show that rare, deleterious variants (RDVs) in a few genes are critical determinants of heritable cancer risk. Better understanding of germline RDVs will contribute to improved precision prevention, screening and treatment.Methods We have performed the largest to date jointly processed germline pan-cancer case-control association study from whole-exome sequencing (WES) data of 20,789 participants, split into discovery and validation cohorts. We focused on high-penetrance RDVs based on ClinVar database. To increase the statistical power, we pursued a collapsing approach and compared the cumulative RDV burden at gene and gene-set levels using penalized logistic regression. Next, we investigated how the accumulation of RDVs in an individual (RDV load) is associated with cancer risk. Finally, we studied how personal RDV load in specific gene-sets affected i) age of diagnosis; ii) tumor immune microenvironment; and iii) tumor mutational burden using Mann-Whitney U test and Kruskal-Wallis test.Results Our results confirm known associations between cancer risk and germline RDVs in BRCA1/2 genes, and show associations with risk for RDVs in Fanconi Anemia (FA), DNA damage repair (DDR), cancer predisposition (CPD) and somatic cancer driver gene-sets in two independent cohorts. Furthermore, increased personal germline RDV load in these gene-sets increased cancer risk, and once cancer developed, tumor characteristics. Notably, we show that the personal RDV load of an individual in FA, DDR or CPD genes is a potential marker for younger age of onset, M1 macrophage fraction in tumor microenvironment, and, in specific cancers, increased tumor mutation burden.Conclusions Our findings will help better stratification of individuals at high cancer risk, as well as the characterization of the influence of their personal germline RDV load on age of diagnosis, tumor microenvironment and mutational burden. These high-risk individuals may benefit from increased surveillance, earlier screening and prevention efforts, and treatments that exploit their tumor characteristics, improving prognosis.Competing Interest StatementS.G. reports consultancy and/or advisory roles for Merck and OncoMed and research funding from Bristol-Myers Squibb, Genentech, Celgene, Janssen R&D, Takeda, and Regeneron. Other authors have no competing interests to declare.Funding StatementThis work was supported by grants to Z.H.G from LUNGevity Foundation, Uniting Against Lung Cancer Foundation; to R.J.K. from the National Cancer Institute (R01 CA167824); and in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. S.G. was supported by grants U24 CA224319 and U01 DK124165.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:TCGA and dbGaP data usage was approved by the relevant data access commitees at NIH under project #8668. The usage of BioME data in our study (HS# 19-01088) was approved by the Program for the Protection of Human Subjects (PPHS) office at the Icahn School of Medicine at Mount Sinai (ISMMS) as exempt human research (IRB-19-02546)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor our discovery cohort, we used case data from TCGA and control data from twelve population-based studies in the database of Genotypes and Phenotypes (dbGaP) (http://www.ncbi.nlm.nih.gov/gap). We downloaded TCGA germline WES bam files from National Cancer Institute Cancer Genomics Hub (cgHub), a predecessor to the Genomic Data Commons (https://portal.gdc.cancer.gov) which is no longer online. We extracted control fastq files from the NCBI Short Read Archive (SRA) for the following dbGaP studies:phs000209, phs000276, phs000296, phs000298, phs000424, phs000654, phs000687, phs000806, phs000876, phs000971, phs001000 and phs001101. For replication, we used the exome calls from BioMe Biobank of Icahn School of Medicine at Mount Sinai (ISMMS). http://www.ncbi.nlm.nih.gov/gap http://biomebiobank.mssm.edu:8080/biobank/service/biobankHome.jsp